Celldex Therapeutics (Celldex Therapeutics) Price-to-Operating-Cash-Flow : (As of Apr. 28, 2024)

View and export this data going back to 1990. Start your Free Trial

What is Celldex Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-04-28), Celldex Therapeutics's share price is $36.30. Celldex Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.21. Hence, Celldex Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Celldex Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

CLDX's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.65
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Celldex Therapeutics's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.63. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.21.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -17.60% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 18.00% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 24.10% per year.

During the past 13 years, Celldex Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 58.40% per year. The lowest was -98.00% per year. And the median was 11.60% per year.

Celldex Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Celldex Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Price-to-Operating-Cash-Flow Chart

Celldex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Celldex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Celldex Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Celldex Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celldex Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Price-to-Operating-Cash-Flow falls into.

Celldex Therapeutics Price-to-Operating-Cash-Flow Calculation

Celldex Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	36.30	/	-2.208
	=

Celldex Therapeutics's Share Price of today is $36.30.
Celldex Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.21.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Celldex Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Celldex Therapeutics (Celldex Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (NAS:CLDX) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

TCE2:Germany

Address

53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827

Website

https://www.celldex.com

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Executives

Garry Arthur Neil	director	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Rita Jain	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Tibor Keler	officer: Sen. VP & Ch Scientific Off.	30 PARK ROAD, OTTSVILLE PA 18942
Sarah Cavanaugh	officer: SVP of Corp. Affairs & Admin.	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Diane C. Young	officer: SVP, Chief Medical Officer	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Anthony S Marucci	director, officer: President and CEO	66 COLD HILL DRIVE, MENDAHM NJ 07945
Richard M. Wright	officer: Sr. VP & CCO	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Samuel Bates Martin	officer: SVP and CFO	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Margo Heath-chiozzi	officer: SVP of of Regulatory Affairs	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Elizabeth Crowley	officer: SVP, Chief Product Dev Officer	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Freddy A. Jimenez	officer: SVP & General Counsel	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
James J Marino	director	C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Keith L Brownlie	director	777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Gerald Phd Mcmahon	director	300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114